A Phase 3 interventional study of Palovarotene in Fibrodysplasia Ossificans Progressiva (FOP), sponsored by Ipsen. Completed at 13 sites in 10 countries. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2025-06-22.
Sponsored by Ipsen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Myositis Ossificans by Ipsen — 1 open to participants now, 1 under way, none of them phase 3. Myositis Ossificans · Ipsen.
Among the 10 studies in Myositis Ossificans by Ipsen, this one is the only one that started in 2022, is one of 2 in phase 3, and was the 8th registered.
24 studies on the registry are indexed under Myositis Ossificans; 5 are open to participants now.
Browse Myositis Ossificans studies →1 of the 10 studies in Myositis Ossificans by Ipsen is open now, in 2 countries. Recruiting first, the newest first:
Ipsen · Sites in United States, Canada
Ages 8+
By country, each count listing its studies:
Of the 4 Myositis Ossificans studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; 4 take children under 18; none take healthy volunteers.
This study: 14 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 61 is above the median of 48 across 16 interventional studies indexed under Myositis Ossificans.
Median enrollment 58 across the 7 interventional studies, 114 across the 3 observational. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
Ipsen is the lead sponsor of 289 studies on the registry; 17 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Myositis Ossificans by Ipsen, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main objective of this study is to further evaluate the safety and efficacy of palovarotene in adult and paediatric participants with FOP.
The aim of the study is also to ensure treatment continuity to participants who have completed one of the parent studies (Study PVO-1A-301, Study PVO-1A-202 and Study PVO-1A-204) and who, in the investigator's judgement, may benefit from palovarotene therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic treatment: participants will receive 5 mg palovarotene or the dose received during participation in the parent study at the time of transition to Study CLIN-60120-452 or prior to interrupting/stopping palovarotene treatment. Flare-up treatment: at the time of a flare-up (or substantial high-risk traumatic event likely to lead to a flare-up) participants will receive 20 mg palovarotene for 28 days, followed by 10 mg palovarotene for 56 days.
Drug: Palovarotene
Palovarotene will be taken orally once daily at approximately the same time each day.
Number of Participants With All Treatment-emergent Adverse Events (TEAEs), Serious and Non-serious Treatment-emergent Adverse Events and Serious and Non-serious Treatment-related Treatment-emergent Adverse Events
An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An SAE was defined as any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or significant medical event. A TEAE was defined as any AE that occurred after signing the informed consent form of this study or an ongoing AE from the parent study with a worsening in severity or relationship to the study treatment following transition to this study.
Time frame: From signing the informed consent form (Day 1) up to 30 days post last dose, approximately 32 months
Change From the Inclusion Visit in Cumulative Analogue Joint Involvement Scale (CAJIS) Total Score at Months 6, 12, 18, 24 and 30
The CAJIS is an objective measure of joint movement completed by the investigator to document total joint involvement. This scale assesses functional disability by categorizing range of motion across 12 joints (both right and left shoulder, elbow, wrist, hip, knee and ankle joints) and 3 body regions (cervical spine, thoracic/lumbar spine and jaw), with each joint/region assessed as: 0=normal (\<10% deficit); 1=partially impaired (10% to 90% deficit) and 2=functionally ankylosed (\>90% deficit). The CAJIS total score is calculated as the sum of the scores of all joints/regions and ranges from 0 (no involvement) to 30 (maximally involved). Higher score indicated worse outcome. The Inclusion Visit was the first study visit (Day 1) and first administration of palovarotene in this study.
Time frame: Inclusion Visit (Day 1) and Months 6, 12, 18, 24 and 30
Change From the Inclusion Visit in the Use of Assistive Devices and Adaptations (Aids) for Daily Living at Months 6, 12, 18, 24 and 30
The use of assistive devices and adaptations (aids) for daily living was collected using the FOP assistive devices assessment at each visit. Assistive devices and adaptations include mobility aids, eating tools, personal care tools, bathroom aids and devices, bedroom aids and devices, home adaptions, work environment adaptions, technology adaptions, sports and recreation adaptions, school adaptions and medical therapies for daily living. The mean of total number of assistive devices and adaptations for daily living being used is presented. The Inclusion Visit was the first study visit (Day 1) and first administration of palovarotene in this study.
Time frame: Inclusion Visit (Day 1) and Months 6, 12, 18, 24 and 30
Change From the Inclusion Visit in Percentage of Worst Score Using the Adult Form of the Fibrodysplasia Ossificans Progressiva Physical Function Questionnaire (FOP-PFQ) at Months 6, 12, 18, 24 and 30
The FOP-PFQ is a disease-specific patient-reported outcome measure of physical impairment; includes 28 questions related to activities of daily living and physical performance scored on a scale of 1 to 5 with lower scores indicating that participant has more difficulty completing those tasks. Total score, upper extremities subscore and mobility subscore is calculated as follows: total score: sum of the scores from each question (range 28 to 140); upper extremities subscore: sum of the scores from 15 questions (questions 1-12, 14, 25 and 26; range 15 to 75); mobility subscore: the sum of the scores from 13 questions (questions 13, 15-24, 27 and 28; range 13 to 65). The scores were transformed to reflect a percentage of worst score which ranged from 0% to 100% with 0% indicating the best possible function and 100% (higher score) indicating the worst possible function. Mean is presented. Inclusion Visit was first study visit (Day 1) and first administration of palovarotene in this study.
Time frame: Inclusion Visit (Day 1) and Months 6, 12, 18, 24 and 30
Annualized Rate of Healthcare Utilization (HU) in Participants With Fibrodysplasia Ossificans Progressiva
Annualized HU rate was defined as the (number of HU during the study/duration of participant participation in the study in days) \* 365.25. Annualized rate for total health care services utilized is presented.
Time frame: Up to approximately 32 months
Change From the Inclusion Visit in Percent Predicted Forced Vital Capacity (FVC) at Months 6, 12, 18, 24 and 30
Lung function parameters including FVC were obtained by spirometry. The Inclusion Visit was the first study visit (Day 1) and first administration of palovarotene in this study.
Time frame: Inclusion Visit (Day 1) and Months 6, 12, 18, 24 and 30
Change From the Inclusion Visit in Percent Predicted Forced Expiratory Volume in One Second (FEV1) at Months 6, 12, 18, 24 and 30
Lung function parameters including FEV1 were obtained by spirometry. The Inclusion Visit was the first study visit (Day 1) and first administration of palovarotene in this study.
Time frame: Inclusion Visit (Day 1) and Months 6, 12, 18, 24 and 30
Change From the Inclusion Visit in Predicted FEV1/FVC Ratio at Months 6, 12, 18, 24 and 30
The ratio of FEV1 to FVC was calculated. Lung function parameters were obtained by spirometry. The Inclusion Visit was the first study visit (Day 1) and first administration of palovarotene in this study.
Time frame: Inclusion Visit (Day 1) and Months 6, 12, 18, 24 and 30
Change From the Inclusion Visit in Percent Predicted Diffusion Capacity of the Lung for Carbon Monoxide (DLCO) at Months 6, 12, 18, 24 and 30
The DLCO test provides information on the efficiency of gas transfer from alveolar air into the bloodstream. The Inclusion Visit was the first study visit (Day 1) and first administration of palovarotene in this study.
Time frame: Inclusion Visit (Day 1) and Months 6, 12, 18, 24 and 30
Change From the Inclusion Visit in Physical and Mental Function Using Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale at Months 6, 12, 18, 24 and 30
The PROMIS Global Health Scale is a patient-reported outcome measure of physical and mental function. The adult form (developed for participants \>=15 years old) was used for all participants,consists of 10 questions from which 2 scores are calculated: global physical health score (GPH) and global mental health (GMH) score, each ranging from 4 (worse health) to 20 (better health). GPH score:sum of scores from Questions 3, 6, 7 and 8 and GMH score:sum of scores from Questions 2, 4, 5 and 10.These scores were converted to a T-score whose distributions were standardized such that value of 50 represented average (mean) for general population and increments of +/- 10 points represented +/- 1 standard deviation away from the norm.Higher T-scores indicated better physical/mental health. A T-score \<50 indicated worse health than general population, while a T-score \>50 indicated better health. Inclusion Visit was first study visit (Day 1) and first administration of palovarotene in this study.
Time frame: Inclusion Visit (Day 1) and Months 6, 12, 18, 24 and 30
Number of Participants With Flare-ups and Flare-up Outcomes
Number of participants with at least 1 flare-up and intercurrent flare-ups since last visit is presented. Intercurrent flare-ups were defined as a new flare-up or marked worsening of the original flare up at any time during a flare-up-based treatment cycle. Outcome of flare-ups resulting in movement restriction and bone formations in participants is presented. Movement restriction includes categories like better, same, slightly worse, moderately worse and severely worse movement than before.
Time frame: Months 6, 12, 18 and 24
Number of Participants With Flare-ups by Body Location
Number of participants with flare-ups by body locations including shoulder, elbow, hip, knee, ankle or foot, back, jaw and submandibular area and other (includes all other locations than mentioned) is presented.
Time frame: Months 6, 12, 18 and 24
Duration of Flare-up at Months 6, 12, 18 and 24
Duration of flare-up was defined as (date of end of flare-up - date of start of flare-up + 1).
Time frame: Months 6, 12, 18 and 24
Percentage of Participants With Extra Bone Growth at Months 6, 12, 18 and 24
Percentage of participants with at least 1 extra bone growth associated or not with a flare-up since last visit is presented.
Time frame: Months 6, 12, 18 and 24
This single-arm, rollover, multicenter, Phase III, open-label study was conducted at 12 investigational sites in 9 countries from 14-Mar-2022 to 30-Nov-2024 in participants \>=14 years with fibrodysplasia ossificans progressiva (FOP) who had completed parent study PVO-1A-301 (NCT03312634) or PVO-1A-202 (NCT02279095)/PVO-1A-204 (NCT02979769) and continued to benefit from palovarotene therapy. A total of 61 participants were enrolled in the study of which 59 received treatment.
| Milestone | Palovarotene |
|---|---|
| Started | 61 |
| Received treatment | 59 |
| Completed | 38 |
| Not completed | 23 |
| Withdrew: Adverse event | 2 |
| Withdrew: Withdrawal by subject | 18 |
| Withdrew: Death | 2 |
| Withdrew: Other | 1 |
An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An SAE was defined as any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or significant medical event. A TEAE was defined as any AE that occurred after signing the informed consent form of this study or an ongoing AE from the parent study with a worsening in severity or relationship to the study treatment following transition to this study.
| Participants | Palovarotene |
|---|---|
| All TEAEs | 54 |
| Serious TEAEs | 9 |
| Non-serious TEAEs | 53 |
| Serious treatment-related TEAEs | 1 |
| Non-serious treatment-related TEAEs | 38 |
The CAJIS is an objective measure of joint movement completed by the investigator to document total joint involvement. This scale assesses functional disability by categorizing range of motion across 12 joints (both right and left shoulder, elbow, wrist, hip, knee and ankle joints) and 3 body regions (cervical spine, thoracic/lumbar spine and jaw), with each joint/region assessed as: 0=normal (\<10% deficit); 1=partially impaired (10% to 90% deficit) and 2=functionally ankylosed (\>90% deficit). The CAJIS total score is calculated as the sum of the scores of all joints/regions and ranges from 0 (no involvement) to 30 (maximally involved). Higher score indicated worse outcome. The Inclusion Visit was the first study visit (Day 1) and first administration of palovarotene in this study.
| score on a scale | Palovarotene |
|---|---|
| Month 6 | 0.6 ± 1.3 |
| Month 12 | 1.1 ± 2.0 |
| Month 18 | 1.5 ± 2.3 |
| Month 24 | 1.5 ± 2.6 |
| Month 30 | 2.0 ± 4.7 |
The use of assistive devices and adaptations (aids) for daily living was collected using the FOP assistive devices assessment at each visit. Assistive devices and adaptations include mobility aids, eating tools, personal care tools, bathroom aids and devices, bedroom aids and devices, home adaptions, work environment adaptions, technology adaptions, sports and recreation adaptions, school adaptions and medical therapies for daily living. The mean of total number of assistive devices and adaptations for daily living being used is presented. The Inclusion Visit was the first study visit (Day 1) and first administration of palovarotene in this study.
| number of aids | Palovarotene |
|---|---|
| Month 6 | -0.7 ± 3.4 |
| Month 12 | 1.1 ± 4.7 |
| Month 18 | 1.4 ± 5.7 |
| Month 24 | 1.2 ± 5.1 |
| Month 30 | 2.8 ± 7.4 |
The FOP-PFQ is a disease-specific patient-reported outcome measure of physical impairment; includes 28 questions related to activities of daily living and physical performance scored on a scale of 1 to 5 with lower scores indicating that participant has more difficulty completing those tasks. Total score, upper extremities subscore and mobility subscore is calculated as follows: total score: sum of the scores from each question (range 28 to 140); upper extremities subscore: sum of the scores from 15 questions (questions 1-12, 14, 25 and 26; range 15 to 75); mobility subscore: the sum of the scores from 13 questions (questions 13, 15-24, 27 and 28; range 13 to 65). The scores were transformed to reflect a percentage of worst score which ranged from 0% to 100% with 0% indicating the best possible function and 100% (higher score) indicating the worst possible function. Mean is presented. Inclusion Visit was first study visit (Day 1) and first administration of palovarotene in this study.
| percentage of score | Palovarotene |
|---|---|
| Month 6: total score | 0.74 ± 6.37 |
| Month 12: total score | 2.39 ± 10.21 |
| Month 18: total score | 4.77 ± 12.39 |
| Month 24: total score | 7.80 ± 15.15 |
| Month 30: total score | 13.79 ± 21.98 |
| Month 6: upper extremities subscore | 0.70 ± 6.87 |
| Month 12: upper extremities subscore | 1.12 ± 8.52 |
| Month 18: upper extremities subscore | 3.24 ± 11.28 |
| Month 24: upper extremities subscore | 5.54 ± 12.42 |
| Month 30: upper extremities subscore | 8.15 ± 11.50 |
| Month 6: mobility subscore | 0.74 ± 9.15 |
| Month 12: mobility subscore | 3.90 ± 14.98 |
| Month 18: mobility subscore | 6.53 ± 17.45 |
| Month 24: mobility subscore | 10.38 ± 23.08 |
| Month 30: mobility subscore | 20.30 ± 36.44 |
Annualized HU rate was defined as the (number of HU during the study/duration of participant participation in the study in days) \* 365.25. Annualized rate for total health care services utilized is presented.
| HU per participant year | Palovarotene |
|---|---|
| Annualized Rate of Healthcare Utilization (HU) in Participants With Fibrodysplasia Ossificans Progressiva | 21.7 ± 31.4 |
Lung function parameters including FVC were obtained by spirometry. The Inclusion Visit was the first study visit (Day 1) and first administration of palovarotene in this study.
| percent predicted FVC | Palovarotene |
|---|---|
| Month 6 | 1.2 ± 5.5 |
| Month 12 | -0.7 ± 6.8 |
| Month 18 | -3.9 ± 9.8 |
| Month 24 | -1.6 ± 5.8 |
| Month 30 | -2.8 ± 3.8 |
Lung function parameters including FEV1 were obtained by spirometry. The Inclusion Visit was the first study visit (Day 1) and first administration of palovarotene in this study.
| percent predicted FEV1 | Palovarotene |
|---|---|
| Month 6 | 1.8 ± 5.9 |
| Month 12 | -3.1 ± 9.6 |
| Month 18 | -5.3 ± 11.8 |
| Month 24 | -3.8 ± 6.6 |
| Month 30 | -10.0 ± 11.1 |
The ratio of FEV1 to FVC was calculated. Lung function parameters were obtained by spirometry. The Inclusion Visit was the first study visit (Day 1) and first administration of palovarotene in this study.
| ratio | Palovarotene |
|---|---|
| Month 6 | 0.0163 ± 0.0574 |
| Month 12 | -0.0323 ± 0.1358 |
| Month 18 | -0.0137 ± 0.0888 |
| Month 24 | -0.0365 ± 0.0994 |
| Month 30 | -0.1268 ± 0.1564 |
The DLCO test provides information on the efficiency of gas transfer from alveolar air into the bloodstream. The Inclusion Visit was the first study visit (Day 1) and first administration of palovarotene in this study.
| percent predicted DLCO | Palovarotene |
|---|---|
| Month 6 | -1.5 ± 7.9 |
| Month 12 | -5.3 ± 12.6 |
| Month 18 | -4.4 ± 16.5 |
| Month 24 | -4.8 ± 11.4 |
| Month 30 | -20.0 ± 20.3 |
The PROMIS Global Health Scale is a patient-reported outcome measure of physical and mental function. The adult form (developed for participants \>=15 years old) was used for all participants,consists of 10 questions from which 2 scores are calculated: global physical health score (GPH) and global mental health (GMH) score, each ranging from 4 (worse health) to 20 (better health). GPH score:sum of scores from Questions 3, 6, 7 and 8 and GMH score:sum of scores from Questions 2, 4, 5 and 10.These scores were converted to a T-score whose distributions were standardized such that value of 50 represented average (mean) for general population and increments of +/- 10 points represented +/- 1 standard deviation away from the norm.Higher T-scores indicated better physical/mental health. A T-score \<50 indicated worse health than general population, while a T-score \>50 indicated better health. Inclusion Visit was first study visit (Day 1) and first administration of palovarotene in this study.
| T-score | Palovarotene |
|---|---|
| Month 6: GPH | -0.6 ± 4.4 |
| Month 12: GPH | -1.7 ± 5.0 |
| Month 18: GPH | -2.9 ± 5.0 |
| Month 24: GPH | -1.9 ± 5.8 |
| Month 30: GPH | -3.9 ± 7.0 |
| Month 6: GMH | -1.0 ± 4.8 |
| Month 12: GMH | -1.5 ± 6.3 |
| Month 18: GMH | -2.3 ± 6.9 |
| Month 24: GMH | -2.2 ± 6.0 |
| Month 30: GMH | -5.7 ± 5.1 |
Number of participants with at least 1 flare-up and intercurrent flare-ups since last visit is presented. Intercurrent flare-ups were defined as a new flare-up or marked worsening of the original flare up at any time during a flare-up-based treatment cycle. Outcome of flare-ups resulting in movement restriction and bone formations in participants is presented. Movement restriction includes categories like better, same, slightly worse, moderately worse and severely worse movement than before.
| Participants | Palovarotene |
|---|---|
| Month 6: at least 1 flare up since last visit | 27 |
| Month 12: at least 1 flare up since last visit | 26 |
| Month 18: at least 1 flare up since last visit | 15 |
| Month 24: at least 1 flare up since last visit | 4 |
| Month 6: intercurrent flare-ups since last visit | 7 |
| Month 12: intercurrent flare-ups since last visit | 4 |
| Month 18: intercurrent flare-ups since last visit | 4 |
| Month 24: intercurrent flare-ups since last visit | 0 |
| Month 6: better movement | 0 |
| Month 6: same movement | 22 |
| Month 6: slightly worse movement | 7 |
| Month 6: moderately worse movement | 5 |
| Month 6: severely worse movement | 1 |
| Month 12: better movement | 1 |
| Month 12: same movement | 17 |
| Month 12: slightly worse movement | 10 |
| Month 12: moderately worse movement | 5 |
| Month 12: severely worse movement | 0 |
| Month 18: better movement | 0 |
| Month 18: same movement | 7 |
| Month 18: slightly worse movement | 7 |
| Month 18: moderately worse movement | 1 |
| Month 18: severely worse movement | 1 |
| Month 24: better movement | 0 |
| Month 24: same movement | 1 |
| Month 24: slightly worse movement | 3 |
| Month 24: moderately worse movement | 0 |
| Month 24: severely worse movement | 1 |
| Month 6: bone formation | 5 |
| Month 12: bone formation | 5 |
| Month 18: bone formation | 1 |
| Month 24: bone formation | 0 |
Number of participants with flare-ups by body locations including shoulder, elbow, hip, knee, ankle or foot, back, jaw and submandibular area and other (includes all other locations than mentioned) is presented.
| Participants | Palovarotene |
|---|---|
| Month 6: shoulder | 8 |
| Month 6: elbow | 3 |
| Month 6: hip | 5 |
| Month 6: knee | 5 |
| Month 6: ankle or foot | 3 |
| Month 6: back | 4 |
| Month 6: jaw and submandibular area | 4 |
| Month 6: other | 14 |
| Month 12: shoulder | 4 |
| Month 12: elbow | 2 |
| Month 12: hip | 5 |
| Month 12: knee | 3 |
| Month 12: ankle or foot | 5 |
| Month 12: back | 2 |
| Month 12: jaw and submandibular area | 3 |
| Month 12: other | 12 |
| Month 18: shoulder | 4 |
| Month 18: elbow | 1 |
| Month 18: hip | 3 |
| Month 18: knee | 2 |
| Month 18: ankle or foot | 2 |
| Month 18: back | 1 |
| Month 18: jaw and submandibular area | 0 |
| Month 18: other | 8 |
| Month 24: shoulder | 1 |
| Month 24: elbow | 0 |
| Month 24: hip | 0 |
| Month 24: knee | 1 |
| Month 24: ankle or foot | 1 |
| Month 24: back | 0 |
| Month 24: jaw and submandibular area | 0 |
| Month 24: other | 2 |
Duration of flare-up was defined as (date of end of flare-up - date of start of flare-up + 1).
| days | Palovarotene |
|---|---|
| Month 6 | 130.7 ± 153.3 |
| Month 12 | 121.7 ± 102.7 |
| Month 18 | 72.4 ± 42.6 |
| Month 24 | 72.3 ± 53.9 |
Percentage of participants with at least 1 extra bone growth associated or not with a flare-up since last visit is presented.
| percentage of participants | Palovarotene |
|---|---|
| Month 6: associated | 8.5 |
| Month 6: not associated | 3.4 |
| Month 12: associated | 8.5 |
| Month 12: not associated | 8.5 |
| Month 18: associated | 1.7 |
| Month 18: not associated | 3.4 |
| Month 24: associated | 0 |
| Month 24: not associated | 3.4 |
Collected over Adverse events and deaths were collected from signing the informed consent form (Day 1) up to 30 days post last dose, approximately 32 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Palovarotene | 2/59 (3.4%) | 9/59 (15.3%) | 45/59 (76.3%) |
| Event | Palovarotene |
|---|---|
| PneumoniaInfections and infestations | 2/59 |
| COVID-19Infections and infestations | 1/59 |
| InfluenzaInfections and infestations | 1/59 |
| Lower respiratory tract infectionInfections and infestations | 1/59 |
| SepsisInfections and infestations | 1/59 |
| Fibula fractureInjury, poisoning and procedural complications | 1/59 |
| Humerus fractureInjury, poisoning and procedural complications | 1/59 |
| Tibia fractureInjury, poisoning and procedural complications | 1/59 |
| Acute pulmonary oedemaRespiratory, thoracic and mediastinal disorders | 1/59 |
| Lung disorderRespiratory, thoracic and mediastinal disorders | 1/59 |
| Event | Palovarotene |
|---|---|
| Dry skinSkin and subcutaneous tissue disorders | 14/59 |
| COVID-19Infections and infestations | 11/59 |
| FallInjury, poisoning and procedural complications | 10/59 |
| Skin abrasionInjury, poisoning and procedural complications | 7/59 |
| Back painMusculoskeletal and connective tissue disorders | 7/59 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 6/59 |
| Upper respiratory tract infectionInfections and infestations | 5/59 |
| PruritusSkin and subcutaneous tissue disorders | 5/59 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 5/59 |
| LymphoedemaVascular disorders | 5/59 |
The full analysis set (FAS)/safety set included all participants who received at least 1 dose of palovarotene in this study.
| Age, Continuous(years) | Palovarotene |
|---|---|
| Mean | 22.4 ± 8.9 |
| Sex: Female, Male(Participants) | Palovarotene |
|---|---|
| Female | 28 |
| Male | 31 |
| Ethnicity (NIH/OMB)(Participants) | Palovarotene |
|---|---|
| Hispanic or Latino | 10 |
| Not Hispanic or Latino | 33 |
| Unknown or Not Reported | 16 |
| Race/Ethnicity, Customized(Participants) | Palovarotene |
|---|---|
| White | 38 |
| Black or African American | 0 |
| Asian | 3 |
| Other | 1 |
| Multiple | 2 |
| Not Reported | 15 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants. Any requests should be submitted to www.vivli.org for assessment by an independent scientific review board.
Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and EU or after the primary manuscript describing the results has been accepted for publication, whichever is later.
Access criteria: Further details on Ipsen's sharing criteria, eligible studies and process for sharing are available here (https://vivli.org/members/ourmembers/).
Data sharing details ↗ · vivli.org
Ran from Mar 2022 to primary completion in Nov 2024, 32 months.
Results were first posted in Jun 2025, 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Palovarotene